ABSTRACT Xenografts from eight human bronchial carcinomas have been established in CBA/Lac mice rendered immunodeficient by neonatal thymectomy followed three weeks later by whole body irradiation (7.35 Gy (735 rads)) after a priming dose of cytosine arabinoside. Growth rates of individual tumour lines remain constant and the histological and chromosomal characteristics of the original tumour are maintained through multiple serial passages over many months. With specific growth delay as the principal end point this system may be used to assess the response of histologically different lung tumours to chemotherapeutic agents.
minority of those with inoperable non-small cell malignancies.2 The great variation in the response of individuals to the currently used drugs and the need to develop more effective agents, particularly for non-small cell tumours, has led to much interest in methods of assessing the efficiency of anticancer treatments in the laboratory.3 The success of in vitro testing of bacterial sensitivities to antibiotics led early workers to attempt to evaluate the effects of anticancer drugs on malignant cells growing in tissue culture and to correlate the results with the clinical response seen in the patient.4 " The results were disappointing,3 although the development of newer clonogenic assays appeared more encouraging.67
Various animal models have been used in the development and testing of new anticancer agents. Transplantable rodent tumours, such as the Lewis lung carcinoma, have proved of little value as appreciable differences in sensitivity between these and human tumours were found. In an attempt to overcome this problem many workers have grown human tumours either in congenitally athymic "nude" mice89 or in rodents rendered immunodeficient by various techniques.'°" We have used such a system and find it a useful animal model for assessing the activity of anticancer agents in bronchial carcinoma. Xenografts attaining a volume of 0.3-1.0 cm3 were used for drug testing. Comparable groups of 6-10 tumours were assembled and randomly allocated to either the treatment or the control group. Drugs were then administered at their maximum tolerated dose and calliper measurements continued until tumours had doubled in volume. The mean tumour doubling time (TD) for each group could then be calculated. The overall response of xenografts to treatment was assessed by measuring the specific tumour growth delay"4 (SGD) (fig 1) , where
The specific grown delay represents the number of tumour doubling times delayed by the treatment and allows comparisons to be made between drugs in tumours of different growth rates. 
